viewTiziana Life Sciences PLC

Tiziana Life Sciences hires scientist with track record of successfully developing blockbuster monoclonal antibody products as its chief medical officer

At Regeneron Pharmaceuticals Inc, Dr Neil Graham was “instrumental” in bringing to market Dupixent and Kevzara


Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS) said it has hired an industry veteran with experience of successfully developing blockbuster monoclonal antibody products as its chief medical officer.

At Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Dr Neil Graham was “instrumental” in bringing to market Dupixent, a blockbuster monoclonal antibody product for eczema and asthma, taking it from phase I to launch.

During his tenure, he also led the product development for Kevzara, an IL-6R antibody for rheumatoid arthritis, which is now also being used to fight coronavirus (COVID-19) symptoms.

Graham’s experience will be crucial during the clinical evolution of Tiziana candidates Foralumab, a monoclonal antibody (mAB) treatment for autoimmune and inflammatory diseases, Milciclib, for cancer, and TZLS-501, its anti-IL-6 drug.

He hailed as a potential “game-changer” the ability to deliver antibody immuno-therapeutics both orally and nasally, an approach being pioneered with Foralumab.

In a statement, Tiziana chairman and founder, Gabriele Cerrone, said of Graham: “His knowledge and experience at Regeneron in developing blockbuster monoclonal antibody drugs such as Dupixent will be invaluable in developing Foralumab and our anti-IL-6 drug, TZLS-501.”

As well as a 10-year stint at Regeneron, Graham has held roles with drug developers Vertex, Trimeris and Glaxo Welcome and he was also an associate professor at John Hopkins University in the US.

Quick facts: Tiziana Life Sciences PLC

Price: 104 GBX

Market: LSE
Market Cap: £202.4 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...


Tiziana Life Sciences reports strong topline data from Foralumab COVID-19 trial

Tiziana Life Sciences PLC's (NASDAQ:TLSA) (LON:TILS) Dr Kunwar Shailubhai discusses with Proactive's Andrew Scott the positive data from its clinical study of nasally administered Foralumab in COVID-19 patients in Brazil. He says CT scans of the lungs showed the improvement was approximately...

on 02/02/2021

2 min read